XMT-2056 is under clinical development by Mersana Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XMT-2056’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XMT-2056 overview

XMT-2056 is under development for the treatment of HER2-expressing solid tumors including breast cancer, gastric cancer, and non-small cell lung cancers. It is administered through intravenous route. It is developed based on immunosynthen platform. The drug candidate acts by targeting STING and cell expressing HER2

Mersana Therapeutics overview

Mersana Therapeutics (Mersana) is a pharmaceutical company. It develops antibody-drug conjugates (ADC) for the treatment of cancer. The company’s pipeline product XMT-1660, XMT-2056, XMT-2068, and XMT-2175 an ADC which targets sodium-dependent phosphate transport protein NaPi2b utilizing Dolaflexin platform. Mersana utilizes various technologies including DolaLock Technology, Dolaflexin, Dolasynthen, and Immunosynthen in developing ADCs. Its products also include ASN004 which is in dose escalation stage. The company develops immunoconjugates to deliver payloads of anti-tumor agents directly to cancerous cells. Its products are used to treat multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of XMT-2056’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.